42
Participants
Start Date
March 31, 2012
Primary Completion Date
February 20, 2023
Study Completion Date
February 20, 2023
Afatinib and Paclitaxel
All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Commack, Commack
University of Southern California, Los Angeles
Massachusetts General Hospital Cancer Center, Boston
Memorial Sloan Kettering Basking Ridge, Basking Ridge
Memorial Sloan Kettering Rockville Centre, Rockville Centre
Memorial Sloan Kettering Monmouth, Middletown
Memorial Sloan Kettering Bergen, Montvale
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
University of Southern California
OTHER
Dana-Farber Cancer Institute
OTHER
United States Department of Defense
FED
Memorial Sloan Kettering Cancer Center
OTHER